Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

SutroVax heading to clinic with potential competitor to Pfizer’s Prevnar 13

March 26, 2020 11:40 PM UTC

With its new $110 million series D round, SutroVax is preparing for its first clinical trial that could test its 24-valent pneumonia vaccine against Prevnar 13 -- or a next-generation version.

RA Capital and Janus Henderson investors led SutroVax Inc.’s round. Also participating were all of the company’s existing institutional investors TPG Growth, Abingworth, Longitude Capital, Frazier Healthcare Partners, Pivotal bioVenture Partners, Medicxi, CTI Life Sciences, Roche Venture Fund and Foresite Capital...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Vaxcyte Inc.